Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 919 East Hillsdale Boulevard, Suite 250 FOSTER CITY CA 94404 |
Tel: | N/A |
Website: | https://www.geron.com |
IR: | See website |
Key People | ||
John A. Scarlett Chairman of the Board, President, Chief Executive Officer | Michelle Robertson Chief Financial Officer, Executive Vice President, Treasurer | Andrew J. Grethlein Executive Vice President, Chief Operating Officer |
Stephen N. Rosenfield Executive Vice President, Corporate Secretary, Chief Legal Officer | Faye Feller Executive Vice President, Chief Medical Officer | Anil Kapur Executive Vice President, Corporate Strategy and Chief Commercial Officer |
Melissa A. Kelly Behrs Executive Vice President - Business Operations, and Chief Alliance Officer | Edward Koval Executive Vice President, Chief Business Officer |
Business Overview |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia. |
Financial Overview |
For the fiscal year ended 31 December 2023, Geron Corp revenues decreased 60% to $237K. Net loss increased 30% to $184.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Development of Therapeutical products segment loss increase of 40% to $193.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.37 to -$0.32. |
Employees: | 141 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,691M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.24M as of Dec 31, 2023 |
EBITDA (TTM): | -$193.50M as of Dec 31, 2023 |
Net annual income (TTM): | -$184.13M as of Dec 31, 2023 |
Free cash flow (TTM): | -$168.57M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 586,912,213 as of Mar 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |